Publications

Export 77 results:
Auteur Title Type [ Année(Desc)]
Filtres: Auteur is Serge Gauthier  [Enlever les filtres]
2016
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H et al..  2016.  Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
Gordon MForrest, Lenderking WR, Duhig A, Chandler J, J Lundy J, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S et al..  2016.  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.  2016.  Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, M Chakravarty M, Gauthier S, Pruessner JC.  2016.  Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al..  2016.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
Schoemaker D, Poirier J, Escobar S, Gauthier S, Pruessner J.  2016.  Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Labbe A et al..  2016.  VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis.. Front Neuroinform. 10:20.
Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton LT.  2016.  Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12(1):60-4.
2017
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P.  2017.  [(18)F]FDG PET signal is driven by astroglial glutamate transport.. Nat Neurosci. 20(3):393-395.
Lajoie I, Nugent S, Debacker C, Dyson K, Tancredi FB, Badhwar AP, Belleville S, Deschaintre Y, Bellec P, Doyon J et al..  2017.  Application of calibrated fMRI in Alzheimer's disease.. Neuroimage Clin. 15:348-358.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Brayet P, Petit D, Baril A-A, Gosselin N, Gagnon J-F, Soucy J-P, Gauthier S, Kergoat M-J, Carrier J, Rouleau I et al..  2017.  Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment.. Sleep Med. 34:134-140.
Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, Peng D, Guo Q, Wu L, Chen S et al..  2017.  Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease.. Alzheimers Dement. 13(5):592-597.
Schoemaker D, Poirier J, D Collins L, Gauthier S, Pruessner JC.  2017.  Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
Maria Rajah N, Wallace LMK, Ankudowich E, Yu EH, Swierkot A, Patel R, M Chakravarty M, Naumova D, Pruessner J, Joober R et al..  2017.  Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife.. Neuroimage Clin. 14:760-774.
Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P.  2017.  Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J et al..  2017.  The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.. J Alzheimers Dis. 56(3):929-938.

Pages